Prognostic impact of eligibility for adjuvant immunotherapy in locally advanced urothelial cancer.
Yuki MiuraShingo HatakeyamaToshikazu TanakaNaoki FujitaHirotaka HoriguchiYoshiharu OkuyamaYuta KojimaDaisuke NoroNoriko TokuiTeppei OkamotoHayato YamamotoHiroyuki ItoTakahiro YoneyamaYasuhiro HashimotoChikara OhyamaPublished in: BJUI compass (2021)
A total of 52% of patients were eligible for adjuvant immunotherapy. Trial eligibility was significantly associated with a poor prognosis. LVI+ and pN+ may play a key role in candidate selection for adjuvant immunotherapy.
Keyphrases
- poor prognosis
- early stage
- end stage renal disease
- locally advanced
- long non coding rna
- chronic kidney disease
- squamous cell carcinoma
- newly diagnosed
- ejection fraction
- rectal cancer
- papillary thyroid
- peritoneal dialysis
- neoadjuvant chemotherapy
- study protocol
- randomized controlled trial
- lymph node
- young adults
- phase ii study
- phase ii
- urinary tract